BPC-157 / TB-500 / KPV

A three-peptide research blend studied in preclinical cellular research models.

Molecular Profile

Type
Peptide blend

Components

BPC-157

Molecular formula
C62H98N16O22
Molecular weight
1,419.5 g/mol
CAS number
137525-51-0
Sequence
GEPPPGKPADDAGLV

TB-500 (full-length acetylated Thymosin Beta-4)

Molecular formula
C212H350N56O78S
Molecular weight
~4,963 g/mol
CAS number
77591-33-4
Sequence
Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES

KPV

Molecular formula
C16H30N4O4
Molecular weight
342.43 g/mol
CAS number
67727-97-3
Sequence
Lys-Pro-Val

Mechanism & Target Class

A three-component formulation combining a gastric-juice-derived pentadecapeptide (BPC-157), a full-length Thymosin Beta-4-related actin-binding peptide (TB-500), and an alpha-MSH-derived tripeptide (KPV). The components are associated in the literature with distinct molecular contexts — VEGFR2/eNOS-related vascular signaling, intracellular G-actin sequestration, and PepT1 transport with NF-kB / MAPK signaling, respectively — and the blend has no single shared target.

Storage & Handling

Lyophilized
-20°C; protect from light; stable months desiccated.
Handling
Multi-peptide blend; component ratios vary by supplier; aliquot to avoid freeze-thaw.

References (29)

  1. Reviews

    1

    Vasireddi N, et al. (2025). HSS Journal

    DOI: 10.1177/15563316251355551PubMed 40756949

  2. 2

    Jozwiak M, et al. (2025). Pharmaceuticals (Basel)

    DOI: 10.3390/ph18020185

  3. 3

    Narrative review (2025). Curr Rev Musculoskelet Med

    DOI: 10.1007/s12178-025-09990-7

  4. 4

    Kleinman HK, Sosne G. (2016). Vitam Horm

    DOI: 10.1016/bs.vh.2016.04.005

  5. 5

    Sikiric P, et al. (2014). Curr Pharm Des

    DOI: 10.2174/13816128113190990411

  6. 6

    Goldstein AL, et al. (2012). Expert Opin Biol Ther

    DOI: 10.1517/14712598.2012.634793PubMed 22074294

  7. 7

    Sikiric P, et al. (2011). Curr Pharm Des

    DOI: 10.2174/138161211796196954PubMed 21548867

  8. 8

    Brzoska T, et al. (2010). Adv Exp Med Biol

    DOI: 10.1007/978-1-4419-6354-3_8

  9. 9

    Brzoska T, et al. (2008). Endocr Rev

    DOI: 10.1210/er.2007-0027PubMed 18612139

  10. 10

    Huff T, et al. (2003). Vitam Horm

    PubMed 12852258

  11. Clinical

    11

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT05984134

  12. 12

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT02597803

  13. 13

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT02637284

  14. 14

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT01311518

  15. 15

    ClinicalTrials.gov. ClinicalTrials.gov

    NCT00832091

  16. Primary research

    16

    He L, et al. (2022). Front Pharmacol

    DOI: 10.3389/fphar.2022.1026182

  17. 17

    Hsieh MJ, et al. (2020). Sci Rep

    PubMed 33051481

  18. 18

    Xiao B, et al. (2017). Mol Ther

    DOI: 10.1016/j.ymthe.2016.11.020PubMed 28143741

  19. 19

    Hsieh MJ, et al. (2017). J Mol Med (Berlin)

    DOI: 10.1007/s00109-016-1488-yPubMed 27847966

  20. 20

    Cox HD, et al. (2017). Drug Test Anal

    DOI: 10.1002/dta.2152PubMed 28035768

  21. 21

    Merlin D, et al. (2016). Cell Mol Gastroenterol Hepatol

    Source

  22. 22

    Chang CH, et al. (2014). Molecules

    DOI: 10.3390/molecules191119066PubMed 25415472

  23. 23

    Xue B, et al. (2014). PNAS

    DOI: 10.1073/pnas.1412271111

  24. 24

    Chang CH, et al. (2011). J Appl Physiol

    DOI: 10.1152/japplphysiol.00945.2010

  25. 25

    Kumar S, Gupta S. (2011). PLoS One

    DOI: 10.1371/journal.pone.0026912

  26. 26

    Dalmasso G, et al. (2008). Gastroenterology

    DOI: 10.1053/j.gastro.2007.10.026PubMed 18061177

  27. 27

    Kannengiesser K, et al. (2008). Inflamm Bowel Dis

    DOI: 10.1002/ibd.20334PubMed 18092346

  28. 28

    Smart N, et al. (2007). Nature

    DOI: 10.1038/nature05383PubMed 17108969

  29. 29

    Bock-Marquette I, et al. (2004). Nature

    DOI: 10.1038/nature03000PubMed 15565145